Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Aug 18;9(8):e70192.
doi: 10.1002/hem3.70192. eCollection 2025 Aug.

Efficacy of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma and prior central nervous system manifestation: A multicenter real-world analysis

Markus Maulhardt  1 , Simon Call  2 , Hristo Boyadzhiev  3   4 , Anca Maria Albici  5 , Keven Hörster  6 , Amelie Boquoi  6 , Snjezana Janjetovic  7 , Anna Ossami Saidy  7 , Marcel Teichert  6 , Annamaria Brioli  8 , Christian Schultze-Florey  8 , Florian Heidel  8 , Philipp Schindler  9 , Natalie Schub  5 , Enver Aydilek  1   10 , Matthias Stelljes  2 , Michael Daskalakis  11 , Carolin Krekeler  2 , Justin Hasenkamp  1 , Cyrus Khandanpour  12 , Ulrike Bacher  11 , Hans Christian Reinhardt  6 , Georg Lenz  2 , Friedrich Stölzel  5 , Thomas Pabst  3 , Bastian von Tresckow  6 , Gerald Wulf  1 , Philipp Berning  2 , Evgenii Shumilov  2
Affiliations

Efficacy of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma and prior central nervous system manifestation: A multicenter real-world analysis

Markus Maulhardt et al. Hemasphere. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

A.B. has participated in advisory boards from BMS, Janssen, GSK, Sanofi, AstraZeneca, and Menarini; received honoraria from Menarini; and received honoraria and travel support from BMS, Janssen, GSK, Sanofi, AstraZeneca, Amgen, and Takeda. M.S. has served as a consultant for Pfizer, MSD, BMS, Incyte, Takeda, Astellas, and Amgen; as a speaker for Pfizer, Medac, MSD, Astellas, Jazz Pharmaceuticals, Amgen, Novartis, Gilead, Celgene, BMS, AbbVie, and Incyte; has received research funding from Pfizer; and has received travel support from Medac and Pfizer. M.D. received support (travel, accommodations, expenses) from Kite‐Gilead, Novartis, Amgen, and Novo Nordisk and served in a consulting or advisory role for Novartis and Alexion Pharma. G.L. received research grants not related to this manuscript from AGIOS, AQUINOX, AstraZeneca, Bayer, Gilead, Janssen, MorphoSys, Novartis, F. Hoffmann‐La Roche Ltd, and Verastem. G.L. received honoraria not related to this manuscript from ADC Therapeutics, AbbVie, Amgen, AstraZeneca, Bayer, BeiGene, BMS, Celgene, Constellation, Genase, Genmab, Gilead, Hexal/Sandoz, Immagene, Incyte, Janssen, Karyopharm, Lilly, Miltenyi, MorphoSys, MSD, NanoString, Novartis, PentixaPharm, Pierre Fabre, F. Hoffmann‐La Roche Ltd, and SOBI. B.v.T. is an advisor or consultant for Allogene, Amgen, BMS/Celgene, Cerus, Gilead Kite, Incyte, IQVIA, Janssen‐Cilag, Lilly, MSD, Miltenyi, Novartis, Noscendo, Pentixapharm, Pfizer, Pierre Fabre, Qualworld, Regeneron, Roche, SOBI, and Takeda; has received honoraria from AbbVie, AstraZeneca, BMS/Celgene, Gilead Kite, Incyte, Janssen‐Cilag, Lilly, MSD, Novartis, Roche, and Takeda; reports research funding from Esteve (Inst.), MSD (Inst.), Novartis (Inst.), and Takeda (Inst.); reports travel support from AbbVie, AstraZeneca, Gilead Kite, Janssen‐Cilag, Lilly, MSD, Pierre Fabre, Roche, Takeda, and Novartis; and is member of steering committees for Regeneron and Takeda. E.S. received honoraria not related to this manuscript from Gilead, Amgen, Sanofi, Oncopeptides, Stemline, Takeda, Pfizer, BMS, and Lilly.

Figures

Figure 1
Figure 1
Clinical courses after treatment with ide‐cel (idecabtagene vicleucel). (A) Swimmer plot depicting clinical courses after chimeric antigen receptor (CAR)‐T treatment for all 10 patients, with systemic (upper line) and central nervous system (CNS)‐specific disease status (lower line) shown for each patient separately. With respect to subsequent therapies after CAR‐T failure, Patient 5 was treated with talquetamab in systemic relapse, whereas Patient 7 received salvage therapies with bortezomib, dexamethasone, cisplatin, doxorubicin, cyclophosphamide, etoposide (VD‐PACE), teclistamab, epirubicin, etoposide, ifosfamide (IEV), and allogeneic stem cell transplantation (alloSCT). Patient 6 received a stem cell boost and salvage therapy with pomalidomide, dexamethasone, and selinexor after CAR‐T failure. Patient 9 opted for best supportive care following refractory disease post‐CAR‐T and declined any further therapy. (B) Kaplan–Meier estimates for patients (pts) with confirmed CNS myeloma showing overall survival (OS) and progression‐free survival (PFS). (C) OS and PFS after propensity score matching with a matched cohort of 24 pts without CNS myeloma. Abbreviations: CR, complete remission; CSF, cerebrospinal fluid; PD, progressive disease; PR, partial remission; SD, stable disease; VGPR, very good partial remission.
See this image and copyright information in PMC

References

    1. Egan PA, Elder PT, Deighan WI, O'Connor SJM, Alexander HD. Multiple myeloma with central nervous system relapse. Haematologica. 2020;105:1780‐1790. - PMC - PubMed
    1. Jurczyszyn A, Grzasko N, Gozzetti A, et al. Central nervous system involvement by multiple myeloma: a multi‐institutional retrospective study of 172 patients in daily clinical practice. Am J Hematol. 2016;91:575‐580. - PMC - PubMed
    1. Paludo J, Painuly U, Kumar S, et al. Myelomatous involvement of the central nervous system. Clin Lymphoma Myeloma Leuk. 2016;16:644‐654. - PubMed
    1. Munshi NC, Anderson LD, Shah N, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384:705‐716. - PubMed
    1. Berdeja JG, Madduri D, Usmani SZ, et al. Ciltacabtagene autoleucel, a B‐cell maturation antigen‐directed chimeric antigen receptor T‐cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE‐1): a phase 1b/2 open‐label study. Lancet. 2021;398:314‐324. - PubMed

LinkOut - more resources